There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Finch Therapeutics Group (FNCH – Research Report), Kezar Life Sciences (KZR – Research Report) and Vera Therapeutics (VERA – Research Report) with bullish sentiments.
Finch Therapeutics Group (FNCH)
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Finch Therapeutics Group today and set a price target of $7.00. The company’s shares closed last Thursday at $0.38, close to its 52-week low of $0.30.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Finch Therapeutics Group with a $7.00 average price target.
See today’s best-performing stocks on TipRanks >>
Kezar Life Sciences (KZR)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Kezar Life Sciences, with a price target of $19.00. The company’s shares closed last Thursday at $2.60, close to its 52-week low of $2.25.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Kezar Life Sciences is a Moderate Buy with an average price target of $19.00.
Vera Therapeutics (VERA)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Vera Therapeutics, with a price target of $10.00. The company’s shares closed last Thursday at $7.55, close to its 52-week low of $5.20.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Currently, the analyst consensus on Vera Therapeutics is a Strong Buy with an average price target of $17.50, a 127.9% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $18.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FNCH:
- Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
- Finch Therapeutics appoints Matthew Blischak CEO
- Finch enters CP101 clinical trial agreement with Brigham and Women’s Hospital
- Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
- Finch Therapeutics price target lowered to $7 from $17 at H.C. Wainwright
